Cai Jing Wang·2025-08-26 03:47Core Insights - BeiGene has announced a royalty transfer agreement with Royalty Pharma for the anti-cancer drug Tarlatamab, with a maximum transaction value of $950 million [1] - The agreement includes an upfront payment of $885 million, with the potential for an additional $65 million within 12 months [1] - BeiGene retains rights to royalties and all other rights for other products, including the dual-targeting antibody XmAb [1] Financial Details - The total potential payment from the agreement could reach $950 million, with $885 million as an upfront payment [1] - An additional $65 million could be obtained by selling the remaining royalty rights within a year [1] - BeiGene will receive a share of revenues from Tarlatamab sales exceeding $1.5 billion annually [1] Product Information - Tarlatamab is a first-in-class immunotherapy that targets DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing tumor cells [1] - The drug has been approved in the U.S. for treating extensive-stage small cell lung cancer (ES-SCLC) after disease progression following platinum-based chemotherapy [1]